Geron Corporation (NASDAQ:GERN) is one of the 10 Best US Penny Stocks to Buy. On December 11, H.C. Wainwright maintained its Neutral rating on Geron Corporation (NASDAQ:GERN) after the company announced a strategic restructuring plan. The plan is designed to position the company for long-term value creation while also improving financial discipline.
The company shared that its strategic restructuring plan is expected to reduce its workforce by about one-third. When Geron Corporation (NASDAQ:GERN) made this announcement, it had around 260 employees in its workforce. The company also expects that this strategic move will help streamline operations and maintain focus on driving RYTELO commercial growth in the US, explore opportunities to make RYTELO available outside the US, and continue making progress on the Phase 3 IMpactMF trial.
H.C. Wainwright noted that Geron Corporation (NASDAQ:GERN) expects its operating expenses in 2026 to be lower than the 2025 levels once most of the cuts are completed in the first quarter of 2026. Based on the guidance on operating expense reduction, the research firm believes the company could reach profitability in the second half of 2026.
In the first half of 2026, Geron Corporation (NASDAQ:GERN) is also expected to share an update on its European commercialization strategy. Additionally, in the second half of 2026, the company expects to share interim overall survival data from the IMpactMF trial.
Geron Corporation (NASDAQ:GERN) is a commercial-stage biopharmaceutical company focused on developing therapies for patients with blood cancers.
While we acknowledge the potential of GERN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 10 Best New Penny Stocks to Invest In and 13 Best Gold Mining Companies to Invest In Now.
Disclosure: None. This article is originally published at Insider Monkey.